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Bacterial infections have always been one of the main reasons of death in the world population. The graph shows some cases in which 
bacteria are involved, still currently generating havoc in humanity. 
 
Seeing the importance of combating bacterial infections due to the damage generated in the world's population, it is vital to encourage 
scientific research in this field. This fact urges them to use all their ingenuity and creativity to counter the adaptive and infectious 
ability of  bacteria. Thus, scientists can make it possible for their research saved thousands of lives. 
 
Moreover, it is a sector that has a broad market. It is the largest after the drugs for the central nervous and cardiovascular system 
market. On the world market, antimicrobials represented 42 billion dollars in 2009, which means 5% of the global pharmaceutical 
market. In 2014, it has been estimated that represents 66 billion. 
This website aims to collect information on about the status of investigations against most current antimicrobials as well as their applications. Being able to thereby provide an overview on 
this field and encouraging interested research groups to form projects. This webpage let these research groups search for new methods and compounds to mitigate bacterial infections. 
There are almost no new molecules for over 30 years. 
Although among them we can find: 
Spanish National Network for the 
discovery of new antibiotics 
A lot of resources has been invested in the 
discovery of new antimicrobials. After proving that 
bacterial infections are no trifle and far of wreak 
ravages only in the third world, it is very 
interesting that the scientific community is 
involved and bet on this area. It is being achieved 
more broadly encompass the bacterial world. Not 
only focusing on finding a new miraculous 
conventional antibiotic, but attempts to diversify 
the problem. This issue may include since 
planktonic bacteria to biofilms, being counteracted 
both antibiotics and antimicrobial peptides. 
Conclusions 
TEIXOBACTIN (2015) 
Teixobactin inhibits cell wall synthesis by binding to 
precursor of peptidoglycan and precursor of cell wall 
teichoic acid. The researchers did not obtain any mutants 
of Staphylococcus aureus or Mycobacterium tuberculosis 
resistant to teixobactin. The properties of this compound 
suggest a path towards developing antibiotics that are 
likely to avoid development of resistance. 2, 3  
ICHip:  
It allows culturing cells in their 
natural environment. Thanks 
to this device, Teixobactin was 
isolated in a soil bacterium 
(Elephtheria terrae). 
Antimicrobial peptides have retained their effectiveness 
against bacteria, avoiding resistances, as acting on a 
design feature, the microbial cell membrane, which 
distinguishes them from plants and animals.  
A biofilm is a population of cells growing in a surface and encapsulated in a matrix of exopolysaccharides. Due to its characteristics, 
biofilms are notoriously difficult to eradicate and are a source of many recalcitrant infections. biofilms are involved as much in dental 
infection as cystic fibrosis, may even invade water pipes. Thanks to its versatility,  they can be applied in very different treatments: 
 
  Therapy against biofilms integrity: Preventive therapy: 
Creating a peptide from 
ECP, a human Rnase. 
 
ECP (x) has given very encouraging results: 
In statewide (Spain) it has been the great 
importance of research into new antibiotics, 
and this past 2014 it was created the “Red 
Nacional Española para el Descubrimiento de 
Nuevos Antibióticos (AD-SP)“ network. This 
was made to combat the shortage of 
innovation in this field and dealing the rise of 
multi-resistant bacteria. 
There are two important families of human antimicrobial 
peptides for their antimicrobial activity. These are 
human ribonucleases and cathelicidins 
Dimensional structure of human RNase; ECP (Eosinophil 
Cationic Protein) and human cathelicidin LL-37, where are 
shown the various regions involved in their activity. 4, 5 
Top 10 causes of death, green shown where bacteria are involved. 1 
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This table shows antimicrobial peptides in treatment and development (2013 ). 6 
This table shows the prevention strategies (2013 ). 7 
This figure contains the results of biofilm dispersion tests and 
antibacterial activity; permeation and membrane depolari-
zation of different peptides including ECP (x) in % against P. 
aeruginosa biofilm formed. These trial were carried out by the 
Department of Biochemistry and molecular biology at the 
Universitat Autònoma de Barcelona. 8 
